News

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field.

The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

Optical coherence tomography will be in all eye care services by October 2025

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).

A case report demonstrates independent effect of GLP-1 receptor agonist.

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.

The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care.

This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.

Afqlir (aflibercept) is a 2 mg vial kit and pre-filled syringe for intravitreal injection.

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.

Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.

Options empower patients and providers to decrease treatment burden